Analysis of physical traits, clinical parameters, and energy metabolism of in vivo- and in vitro-derived Flemish newborn calves during the first day of life.

Studies investigating physiological deviations from normality in newborn calves derived from in vitro fertilization procedures remain important for the understanding of factors that reduce calf survival after birth. The aim of this study was to investigate parameters affecting health and welfare of newborn Flemish calves derived from in vitro embryo production (IVP) in the first hours of life in comparison to in vivo-derived calves. Physical traits of newborn calves and fetal membranes (FM) were recorded soon after birth. Newborn venous blood samples were collected at several time points within the first 24 h of life for analyses of energy substrates, electrolytes, blood gases, acid-base balance, blood chemistry, and haematology. A liver biopsy was taken within the first hour after birth for analysis of gene expression of key enzymes of the fructolytic and glycolytic pathways. Newborn IVP calves were heavier and larger at birth, which was associated with heavier FM. At several time points during the first 24 h of life, IVP-derived calves had altered rectal temperature, blood gases, electrolyte concentrations, blood parameters for liver, kidney and muscle function, and acid-base balance, plasma lipid metabolism, and hemogram parameters. The relative mRNA abundances for triokinase and lactate dehydrogenase-B were greater in IVP calves. In summary, IVP-derived newborn calves were at higher risk of clinical problems after birth, which was markedly greater in heavier and larger calves. Such animals take longer to adapt to extrauterine life and should receive a special attention during the immediate neonatal period.

Physiological impact of the environment on the welfare of transgenic goats raised in a tropical climate.

The present study evaluated the general welfare state of two strains of transgenic goats bred in a region with a hot and humid tropical climate. Nine females were used, being three transgenic for human lysozyme (hLZ group), three transgenic for human glucocerebrosidase (hGCase group), and three non-transgenic (control group). The temperature and humidity index (THI) were recorded during the morning, afternoon, and evening. The physiological parameters measured were respiratory rate, heart rate, and rectal and vaginal temperatures. Venous blood samples were collected using Vacutainer® tubes containing 10% ethylenediaminetetraacetic acid (EDTA). Also, analysis of erythrogram, leukogram, and some biochemical parameters of serum was performed. It was observed that the afternoon shift presented the largest THI, being potentially more impactful on the physiology of animals. In general, respiratory and heart rates were higher in transgenic animals, especially in the hLZ group compared to the control group (P < 0.05). Regarding the hematological parameters, the quantification of red blood cells, hemoglobin, and hematocrit was significantly lower (P < 0.05) in the hGCase group compared to that in the hLZ and control. The leukocyte count was considerably lower (P < 0.05) in the hLZ group compared to that in the hGCase and control. Correlation analysis showed that the increase in THI was associated with a change in physiological parameters normally used as indicators of thermal stress. Despite the differences found among the experimental groups, all the physiological parameters remained within the normal limits recommended for the goat species. Further studies involving a larger number of animals from different categories should be carried out to elucidate the impacts that transgenesis can have on animal welfare under different THI conditions.

Plasma rico em plaquetas e células tronco no tratamento de desmopatia dos ligamentos colaterais distais em equino / Platelet-rich plasma and stem cells in the treatment of desmopathy of the distal collateral ligaments in equine

Os equinos são animais muito utilizados em eventos esportivos, sendo, desta forma, propensos a sofrer acidentes que podem levar a lesões articulares e ósseas. Na rotina clínica, artifícios como o uso de raio X e ultrassonografia são de grande importância para que o correto diagnóstico seja feito e a conduta clínica possa ser melhor planejada. Além disso, alguns biomateriais, como o plasma rico em plaquetas (PRP) e células-tronco mesenquimais (CTMs), têm se inserido nos protocolos terapêuticos, demonstrando grande efetividade no tratamento desse tipo de lesão, devido à grande quantidade de fatores de crescimento presentes em ambos os biomateriais. O PRP é um derivado sanguíneo, caracterizado pela alta concentração plaquetária. Foi produzido a partir de duas centrifugações, a primeira para separar o plasma das hemácias e a segunda para concentrar as plaquetas. As CTMs foram isoladas de tecido adiposo, cultivadas, transportadas e aplicadas de forma autóloga, assim como o PRP. No presente relato, um equino, fêmea, Brasileiro de Hipismo com 8 anos, foi diagnosticado com desmopatia nos ligamentos colaterais da articulação interfalângica distal e foi tratado com PRP e CTMs, de forma associada e sequencial. Foi encontrada uma melhora do quadro clínico, significativa, em comparação aos dados encontrados na literatura, demonstrando grande potencialidade do uso associado de PRP e CTMs no tratamento de lesões ligamentares.

Horses are animals widely used in sporting events and are therefore prone to accidents that can lead to joint and bone injuries. In the clinical routine, devices such as the use of X-ray and ultrasound are of great importance for the correct diagnosis to be made and the clinical conduct can be better planned. In addition, some biomaterials such as platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) have been included in the therapeutic protocols, demonstrating great effectiveness in the treatment of this type of injury due to the large amount of growth factors present in both biomaterials. PRP is a blood derivative, characterized by high platelet concentration. It is produced from two centrifugations, the first to separate plasma from red blood cells and the second to concentrate platelets. MSCs were isolated from adipose tissue, cultured, transported and applied autologously, as well as PRP. In the present report, an 8-year-old female Brazilian equestrian horse was diagnosed with desmopathy in the collateral ligaments of the distal interphalangeal joint and was treated with PRP and MSCs in an associated and sequential manner. A significant improvement in the clinical picture was found in comparison to the data found in the literature, demonstrating great potential of the associated use of PRP and MSCs in the treatment of ligament injuries.

Application of a cost-effective DNA extraction protocol for screening transgenic and CRISPR-edited primary goat cells.

The genotyping of genetically-modified cells is a crucial step in studies of transgenics and genomic editing with systems such as CRISPR/Cas. The detection of genome editing events can be directly related to the genotyping methodology used, which is influenced by its costs, since many experiments require the analysis of a large number of samples. The aim of this study was to compare the performance of direct lysis methods of genomic DNA (gDNA) extraction for the detection of knockins and knockouts in primary goat cells. Initially, three gDNA extraction protocols (protocol A, heat denaturation/freeze-thaw in water; protocol B, heat denaturation/proteinase K; and protocol C, CellsDirect Kit) were tested using different quantities (1,000, 5,000 and 10,000 cells) and types of goat primary cells (fibroblasts and goat mammary epithelial cells-GMECs) for subsequent validation by PCR amplification of small (GAPDH) and large amplicons (hLF transgene). All protocols were successful in the detection of the small amplicon; however, in GMECs, only protocol B resulted efficient amplification (protocol A-0%, protocol B-93%, protocol C-13.33%, P <0.05). In a proof-of-principle experiment, the TP53 gene was knocked out in GMECs by CRISPR/Cas9-mediated deletion while constructs containing the anti-VEGF monoclonal antibody (pBC-anti-VEGF) and bacterial L-Asparaginase (pBC-ASNase) transgenes were knocked-in separately in fibroblasts. Detection of successful editing was performed using protocol B and PCR. The integration rates of the pBC-ASNase and pBC-anti-VEGF transgenes were 93.6% and 72%, respectively, as per PCR. The efficiency of biallelic editing in GMECs using CRISPR/Cas9 for the TP53 deletion was 5.4%. Our results suggest that protocol B (heat denaturation/proteinase K) can be used as an inexpensive and quick methodology for detecting genetic modifications in different types of primary goat cells, with efficiency rates consistent with values previously described in the literature when using extraction kits or more complex proteinase K formulations.

Expression of a recombinant bacterial L-asparaginase in human cells.

OBJECTIVE: L-Asparaginase (ASNase) is an enzyme used in the treatment of acute lymphoblastic leukemia (ALL). As the therapeutic ASNases has bacterial origin, severe side effects are associated with its use, among them hypersensitivity and inactivation of the enzyme. In this context, the objective of this work was to produce a recombinant ASNase of bacterial origin in human cells in order to determine the presence and consequences of potential post-translational modifications on the enzyme. RESULTS: Recombinant ASNase was expressed in human cells with a molecular weight of 60 kDa, larger than in Escherichia coli, which is 35 kDa. N-glycosylation analysis demonstrated that the increased molecular weight resulted from the addition of glycans to the protein by mammalian cells. The glycosylated ASNase presented in vitro activity at physiological pH and temperature. Given that glycosylation can act to reduce antigenicity by masking protein epitopes, our data may contribute to the development of an alternative ASNase in the treatment of ALL in patients who demonstrate side effects to currently marketed enzymes.

Maturação in vitro de oócitos ovinos submetidos à congelação lenta / In vitro maturation of cryopreserved ovine oocytes subjected to slow freezing

A maturação in vitro de oócitos submetidos ao processo de criopreservação, ainda compreende um desafio para o sucesso da reprodução assistida na medicina veterinária. Devido a isso, estudos são desenvolvidos a fim de identificar, amenizar e superar as limitações encontradas. Nesse sentido, objetivou-se realizar a avaliação da maturação in vitro de oócitos ovinos após criopreservação pelo método de congelação lenta. Para tanto, foram colhidos 204 ovários oriundos de 102 ovelhas púberes (SPRD) pertencentes a abatedouros localizados no município de Teresina, Piauí. Os ovários foram transportados para o laboratório e, posteriormente, foram aspirados por meio de um aspirador cirúrgicoadaptado. Um total de 180 oócitos foram desnudados e, então, submetidos à congelação lenta em sistema automatizado (TK 3000®). Posteriormente foram descongelados, e submetidos à maturação in vitro(MIV). Em seguida, procedeu-se a avaliação da maturação nuclear. Os resultados foram avaliados por meio do teste de Qui-quadrado de Pearson (P ≤ 0,05). Após descongelação, 22,8% dos oócitos na avaliação em estereomicroscópio (45x) apresentavam lesões de zona pelúcida e de oolema. Dos 139 oócitos submetidos a MIV, oito maturaram (5,75%). Conclui-se que a congelação lenta de oócitos ovinos pode influenciar a maturação in vitro, devido a lesões de membrana plasmática e zona pelúcida.(AU)

The in vitro maturation of oocytes submitted to the cryopreservation process, still comprises a challenge for the success of assisted reproduction in veterinary medicine. Due to this, studies are developed in order to identify, ameliorate and overcome the limitations found. The objective of this study was to evaluate the in vitro maturation of ovine oocytes after cryopreservation by the slow freezing method. For that, 204 ovaries from 102 pubertal sheep (SPRD) belonging to slaughterhouses located in the city of Teresina, Piauí, were collected. The ovaries were transported to the laboratory and subsequently aspirated by means of an adapted surgical aspirator. A total of 180 CCO's were obtained, which were stripped and then subjected to slow freezing in an automated system (TK 3000®). Later they were thawed and submitted to in vitro maturation (IVM). Next, the nuclear maturation was evaluated. Results were evaluated using Pearson's chi-square test (P ≤ 0.05). After thawing, 22.8% of the oocytes in the stereomicroscope (45x) evaluation presented lesions of the zona pellucida and oolema. Of the 139 oocytes submitted to IVM, eight maturated (5.75%). It is concluded that slow freezing of sheep oocytesmay influence in vitro maturation due to plasma membrane and zona pellucida lesions.(AU)

Maturação in vitro de oócitos ovinos submetidos à congelação lenta / In vitro maturation of cryopreserved ovine oocytes subjected to slow freezing

A maturação in vitro de oócitos submetidos ao processo de criopreservação, ainda compreende um desafio para o sucesso da reprodução assistida na medicina veterinária. Devido a isso, estudos são desenvolvidos a fim de identificar, amenizar e superar as limitações encontradas. Nesse sentido, objetivou-se realizar a avaliação da maturação in vitro de oócitos ovinos após criopreservação pelo método de congelação lenta. Para tanto, foram colhidos 204 ovários oriundos de 102 ovelhas púberes (SPRD) pertencentes a abatedouros localizados no município de Teresina, Piauí. Os ovários foram transportados para o laboratório e, posteriormente, foram aspirados por meio de um aspirador cirúrgicoadaptado. Um total de 180 oócitos foram desnudados e, então, submetidos à congelação lenta em sistema automatizado (TK 3000®). Posteriormente foram descongelados, e submetidos à maturação in vitro(MIV). Em seguida, procedeu-se a avaliação da maturação nuclear. Os resultados foram avaliados por meio do teste de Qui-quadrado de Pearson (P ≤ 0,05). Após descongelação, 22,8% dos oócitos na avaliação em estereomicroscópio (45x) apresentavam lesões de zona pelúcida e de oolema. Dos 139 oócitos submetidos a MIV, oito maturaram (5,75%). Conclui-se que a congelação lenta de oócitos ovinos pode influenciar a maturação in vitro, devido a lesões de membrana plasmática e zona pelúcida.

The in vitro maturation of oocytes submitted to the cryopreservation process, still comprises a challenge for the success of assisted reproduction in veterinary medicine. Due to this, studies are developed in order to identify, ameliorate and overcome the limitations found. The objective of this study was to evaluate the in vitro maturation of ovine oocytes after cryopreservation by the slow freezing method. For that, 204 ovaries from 102 pubertal sheep (SPRD) belonging to slaughterhouses located in the city of Teresina, Piauí, were collected. The ovaries were transported to the laboratory and subsequently aspirated by means of an adapted surgical aspirator. A total of 180 CCO's were obtained, which were stripped and then subjected to slow freezing in an automated system (TK 3000®). Later they were thawed and submitted to in vitro maturation (IVM). Next, the nuclear maturation was evaluated. Results were evaluated using Pearson's chi-square test (P ≤ 0.05). After thawing, 22.8% of the oocytes in the stereomicroscope (45x) evaluation presented lesions of the zona pellucida and oolema. Of the 139 oocytes submitted to IVM, eight maturated (5.75%). It is concluded that slow freezing of sheep oocytesmay influence in vitro maturation due to plasma membrane and zona pellucida lesions.

Developmental Outcome and Related Abnormalities in Goats: Comparison Between Somatic Cell Nuclear Transfer- and In Vivo-Derived Concepti During Pregnancy Through Term.

Cloning by somatic cell nuclear transfer (SCNT) is characterized by low efficiency and the occurrence of developmental abnormalities, which are rather poorly studied phenomena in goats. This study aimed at comparing overall SCNT efficiency in goats by using in vitro-matured (IVM) or in vivo-matured oocytes and fibroblast donor cells (mock transfected, transgenic, or wild type), also characterizing symptoms of the Abnormal Offspring Syndrome (AOS) in development, comparing results with pregnancies produced by artificial insemination (AI) and in vivo-derived (IVD) embryos. The SCNT group had lower pregnancy rate (18.3%, 11/60), total number of concepti (20.0%, 12/60), term births (3.3%, 2/60), and live births (1.7%, 1/60) than both the IVD (77.8%, 7/9; 155.5%, 14/9; 122.2%, 11/9; 88.8%, 8/9) and the AI (71.4%, 10/14; 121.4%, 17/14; 100%, 14/14; 78.5%, 11/14) groups, respectively (p < 0.05). No SCNT pregnancies reached term using IVM oocytes, but in vivo-matured oocytes resulted in two term transgenic cloned kids. The proportion fetal membrane (FM) weight/birth weight reflected an increase in FM size and cotyledonary enlargement in clones, for disproportionally bigger newborns in relation to cotyledonary numbers. Overall, goat cloning showed losses and abnormality patterns similar to the AOS in cloned cattle and sheep, which have not been previously well recognized in goats.

Production of recombinant therapeutic proteins in genetically engineered animals: the dawn of a new era / Produção de proteínas terapêuticas recombinantes em animais geneticamente modificados: o surgimento de uma nova era

Background: The production of transgenic animals has been envisioned as a viable strategy to improve food quality, animal yield, and for the production of bioproducts that can be used for the benefit of the human and animal population. Transgenic animals have been used to improve production traits, to add value to animal products, to minimize the impact on the environment, to promote disease resistance, and most notably, to produce recombinant proteins in natural fluids, such as milk, that can be collected, purified and used as biomedical products (biopharming). This review aims to discuss past and recent technological advances in animal transgenesis, and the perspective for biopharming in Brazil.Review: Since the production of recombinant human insulin from Escherichia coli in the 1970s, continuous development of new platforms has allowed a significant expansion in the biopharmaceutical market. The animal platform has been shown to be highly competitive by adding value as low cost implementation, production and scale up, as well as high productivity of synthesized proteins. The expression of recombinant proteins in milk represents the most developed system for production of biopharmaceutical drugs in animals, with two approved biopharmaceuticals for human use: Atryn®, a recombinant antithrombin produced in the milk of goats, approved in 2006 by European Medicines Agency (EMA) and in 2009 by US Food and Drug Administration (FDA), and more recently, Ruconest®, a recombinant human C1 esterase inhibitor protein (C1INH) produced in the milk of rabbits, first approved by EMA in 2012, followed by the FDA approval in 2014. Transgenic animals have been produced by many strategies that have gradually evolved over the decades, including the use of embryo microinjection, viral vectors and transposable elements, sperm-mediated gene transfer, and cloning by somatic cell nuclear transfer (SCNT).[...](AU)

Production of recombinant therapeutic proteins in genetically engineered animals: the dawn of a new era / Produção de proteínas terapêuticas recombinantes em animais geneticamente modificados: o surgimento de uma nova era

Background: The production of transgenic animals has been envisioned as a viable strategy to improve food quality, animal yield, and for the production of bioproducts that can be used for the benefit of the human and animal population. Transgenic animals have been used to improve production traits, to add value to animal products, to minimize the impact on the environment, to promote disease resistance, and most notably, to produce recombinant proteins in natural fluids, such as milk, that can be collected, purified and used as biomedical products (biopharming). This review aims to discuss past and recent technological advances in animal transgenesis, and the perspective for biopharming in Brazil.Review: Since the production of recombinant human insulin from Escherichia coli in the 1970s, continuous development of new platforms has allowed a significant expansion in the biopharmaceutical market. The animal platform has been shown to be highly competitive by adding value as low cost implementation, production and scale up, as well as high productivity of synthesized proteins. The expression of recombinant proteins in milk represents the most developed system for production of biopharmaceutical drugs in animals, with two approved biopharmaceuticals for human use: Atryn®, a recombinant antithrombin produced in the milk of goats, approved in 2006 by European Medicines Agency (EMA) and in 2009 by US Food and Drug Administration (FDA), and more recently, Ruconest®, a recombinant human C1 esterase inhibitor protein (C1INH) produced in the milk of rabbits, first approved by EMA in 2012, followed by the FDA approval in 2014. Transgenic animals have been produced by many strategies that have gradually evolved over the decades, including the use of embryo microinjection, viral vectors and transposable elements, sperm-mediated gene transfer, and cloning by somatic cell nuclear transfer (SCNT).[...]

Clonagem animal: a sobrevivência dos mais aptos / Animal cloning: survival of the fittest

A clonagem animal por transferência nuclear de célula somática (TNCS) apresenta inúmeras aplicações científicas e comerciais, incluindo a produção de animais transgênicos, a preservação de animais de genética desejável, rara ou em extinção, ou mesmo a aplicação para o estudo de aspectos básicos em biologia molecular, celular e do desenvolvimento. Não obstante, a clonagem por TNCS ainda é ineficiente, com menos de 5% dos embriões clones produzidos resultando em animais nascidos vivos. O sucesso na clonagem exige o exímio domínio técnico e científico de várias disciplinas e áreas de conhecimento, havendo pelo menos cinco etapas críticas no processo associadas a falhas de desenvolvimento, desde a produção in vitro dos embriões até o nascimento de um animal viável. A identificação de fatores associados às falhas em cada etapa, em especial aqueles relacionados ao oócito receptor (citoplasto), à célula doadora (carioplasto) e aos procedimentos técnicos per se de produção de embriões clones, além da observação cuidadosa dos sinais de anormalidades subsequentes à transferência dos embriões para fêmeas receptoras, é essencial para a optimização de todos os procedimentos para a obtenção, em seu final, de um animal clonado viável e que sobreviva até a vida adulta. Esta revisão visa descrever alguns eventos técnicos e biológicos associados ao sucesso e/ou insucesso da clonagem animal.(AU)

Animal cloning by somatic cell nuclear transfer (SCNT) has numerous scientific and commercial applications, including the production of transgenic animals, preservation of animals from desirable or rare gene pools, and animals in risk of extinction, or even for the study of basic aspects in molecular, cell and developmental biology. Nevertheless, cloning by SCNT is still inefficient, with less than 5% of cloned embryos resulting in liveborn animals. The cloning success depends on a proficient technical and scientific know-how of a number of disciplines and areas of knowledge, with at least five critical steps in the process associated with developmental failures, from the in vitro production of cloned embryos through the birth of a viable animal. The identification of factors associated with failures in each step, in special to those related to the recipient oocyte (cytoplast), to the nucleus donor cell (karyoplast), and to the technical procedures for the production of cloned embryos per se, along with the careful observation of signs of abnormalities following the transfer of embryos to recipient females, is essential for the optimization of procedures that, ultimately, may result in a cloned animal that survives to adulthood. This review aims to discuss some technical and biological events associated with success and/or failure in animal cloning.(AU)

Efficient RNAi-induced protein knockdown in somatic cells using diced or chemically produced small interfering RNAs (siRNA)

Background: RNA interference (RNAi) is a post-transcriptional gene silencing process in which double-stranded RNA (dsRNA) directs the degradation of a specific corresponding target mRNA. The mediators of this process are small dsRNAs of approximately 21 to 23 bp in length, called small interfering RNAs (siRNAs), which can be prepared in vitro and used to direct the degradation of specific mRNAs inside cells. Hence, siRNAs represent a powerful tool to study and control gene and cell function. Rapid progress has been made in the use of siRNA as a means to attenuate the expression of any protein for which the cDNA sequence is known. Individual siRNAs can be chemically synthesized, in vitro-transcribed, or expressed in cells from siRNA expression vectors. However, screening for the most efficient siRNAs for post-transcriptional gene silencing in cells in culture is a laborious and expensive process. In this study, the effectiveness of two siRNA production strategies for the attenuation of abundant proteins for DNA repair were compared in human cells: (a) the in vitro production of siRNA mixtures by the Dicer enzyme (Diced siRNAs); and (b) the chemical synthesis of very specific and unique siRNA sequences (Stealth RNaiTM). Materials, Methods & Results: For in vitro-produced siRNAs, two segments of the human Ku70 (167 bp in exon 5; and 249 bp in exon 13; NM001469) and Xrcc4 (172 bp in exon 2; and 108 bp in exon 6; NM003401) genes were chosen to generate dsRNA for subsequent "Dicing" to create mixtures of siRNAs. The Diced fragments of siRNA for each gene sequence were pooled and stored at -80ºC. Alternatively, chemically synthesized Stealth siRNAs were designed and generated to match two very specific gene sequence regions for each target gene of interest (Ku70 and Xrcc4). HCT116 cells were plated at 30% confluence in 24- or 6-well culture plates. The next day, cells were transfected by lipofection with either Diced or Stealth siRNAs for Ku70 or Xrcc4, in duplicate, at various doses, with blank and sham transfections used as controls. Cells were harvested at 0, 24, 48, 72 and 96 h post-transfection for protein determination. The knockdown of specific targeted gene products was quantified by Western blot using GAPDH as control. Transfection of gene-specific siRNA to either Ku70 or Xrcc4 with both Diced and Stealth siRNAs resulted in a down regulation of the targeted proteins to approximately 10 to 20% of control levels 48 h after transfection, with recovery to pre-treatment levels by 96 h. Discussion: By transfecting cells with Diced or chemically synthesized Stealth siRNAs, Ku70 and Xrcc4, two highly expressed proteins in cells, were effectively attenuated, demonstrating the great potential for the use of both siRNA production strategies as tools to perform loss of function experiments in mammalian cells. In fact, down-regulation of Ku70 and Xrcc4 has been shown to reduce the activity of the non-homologous end joining DNA pathway, a very desirable approach for the use of homologous recombination technology for gene targeting or knockout studies. Stealth RNAiTM was developed to achieve high specificity and greater stability when compared with mixtures of enzymatically-produced (Diced) siRNA fragments. In this study, both siRNA approaches inhibited the expression of Ku70 and Xrcc4 gene products, with no detectable toxic effects to the cells in culture. However, similar knockdown effects using Diced siRNAs were only attained at concentrations 10-fold higher than with Stealth siRNAs. The application of RNAi technology will expand and continue to provide new insights into gene regulation and as potential applications for new therapies, transgenic animal production and basic research.

Clonagem animal: a sobrevivência dos mais aptos / Animal cloning: survival of the fittest

A clonagem animal por transferência nuclear de célula somática (TNCS) apresenta inúmeras aplicações científicas e comerciais, incluindo a produção de animais transgênicos, a preservação de animais de genética desejável, rara ou em extinção, ou mesmo a aplicação para o estudo de aspectos básicos em biologia molecular, celular e do desenvolvimento. Não obstante, a clonagem por TNCS ainda é ineficiente, com menos de 5% dos embriões clones produzidos resultando em animais nascidos vivos. O sucesso na clonagem exige o exímio domínio técnico e científico de várias disciplinas e áreas de conhecimento, havendo pelo menos cinco etapas críticas no processo associadas a falhas de desenvolvimento, desde a produção in vitro dos embriões até o nascimento de um animal viável. A identificação de fatores associados às falhas em cada etapa, em especial aqueles relacionados ao oócito receptor (citoplasto), à célula doadora (carioplasto) e aos procedimentos técnicos per se de produção de embriões clones, além da observação cuidadosa dos sinais de anormalidades subsequentes à transferência dos embriões para fêmeas receptoras, é essencial para a optimização de todos os procedimentos para a obtenção, em seu final, de um animal clonado viável e que sobreviva até a vida adulta. Esta revisão visa descrever alguns eventos técnicos e biológicos associados ao sucesso e/ou insucesso da clonagem animal.

Animal cloning by somatic cell nuclear transfer (SCNT) has numerous scientific and commercial applications, including the production of transgenic animals, preservation of animals from desirable or rare gene pools, and animals in risk of extinction, or even for the study of basic aspects in molecular, cell and developmental biology. Nevertheless, cloning by SCNT is still inefficient, with less than 5% of cloned embryos resulting in liveborn animals. The cloning success depends on a proficient technical and scientific know-how of a number of disciplines and areas of knowledge, with at least five critical steps in the process associated with developmental failures, from the in vitro production of cloned embryos through the birth of a viable animal. The identification of factors associated with failures in each step, in special to those related to the recipient oocyte (cytoplast), to the nucleus donor cell (karyoplast), and to the technical procedures for the production of cloned embryos per se, along with the careful observation of signs of abnormalities following the transfer of embryos to recipient females, is essential for the optimization of procedures that, ultimately, may result in a cloned animal that survives to adulthood. This review aims to discuss some technical and biological events associated with success and/or failure in animal cloning.

Microbiological and functional evaluation of an alternative device (OB®) for estrous synchronization in ewes / Avaliação microbiológica e funcional de um dispositivo vaginal alternativo (OB®) para sincronização de cio em ovelhas

The use of synthetic progestagens released by vaginal devices is an important tool to overcome the reproductive seasonality in sheep, but cost and/or subsequent vaginitis are limiting factors for their use. To identify economic, simple and innocuous alternative vaginal devices for estrous synchronization/induction protocols in sheep, this study aimed to evaluate the microbiological and functional viability of the human vaginal tampons (OB®) impregnated with medroxyprogesterone acetate (MAP) on reproductive performance of ewes. The study compared them with commercial vaginal inserts (CIDR®) and polyurethane sponges impregnated with MAP. In Experiment 1, the device loss rate, the degree of vaginitis during the device removal, the count and identification of bacterial colonies at the device insertion and removal, and efficiency in estrous synchronization and estrus temporal distribution were evaluated. Pubertal ewes at the beginning of the breeding season were randomly allocated to three experimental groups: CIDR®, PSP (polyurethane sponge) and OB®. No device losses occurred in any group, but the use of OB® caused milder signs of vaginitis than polyurethane sponges, with a similar vaginal bacterial growth and microbiota than the CIDR group. The estrus distribution was more disperse in the CIDR than PSP or OB groups. In Experiment 2, pregnancy rates using CIDR® or OB® devices were compared, with estrus manifestation (85.4 percent and 89.8 percent) and pregnancy rates (58.3 percent and 49.0 percent) being similar between groups (P>0.05), respectively. In conclusion, the use of human intra-vaginal tampons (OB®) impregnated with MAP was proven highly hygienic, practical and effective as a low-cost alternative for estrous synchronization and AI in sheep.

O uso de progestágeno sintético liberado por pessários vaginais é uma importante ferramenta para suplantar a sazonalidade reprodutiva em ovelhas. Todavia, seu uso é limitado pelo custo ou pelas subsequentes vaginites. Na busca de uma alternativa simples e de baixo custo para sincronizar estro em ovelhas, este estudo avaliou o tampão vaginal humano (OB®) impregnado com MAP, na performance reprodutiva de ovelhas, comparando com o CIDR® e as esponjas de poliuretano, estas também impregnadas com MAP. No experimento 1 foram avaliados a taxa de perdas; o grau das vaginites no momento da remoção do pessário; a contagem e identificação das colônias bacterianas; bem como a eficiência da sincronização e a distribuição temporal dos cios. As ovelhas foram aleatoriamente distribuídas em um de três grupos experimentais: CIDR, Esponjas e OB, no inicio da estação reprodutiva. Não ocorreram perdas de pessários em qualquer grupo, porém o OB causou menor grau de vaginite em relação às esponjas, com um crescimento bacteriano e microbiota similares ao grupo CIDR. A distribuição dos cios foi mais dispersa no grupo CIDR do que nos grupos Esponja ou OB. No experimento 2, foram comparados o CIDR e OB em relação à manifestação de cio (85,4 por cento e 89,8 por cento) e taxa de prenhez (58,3 por cento e 49,0 por cento), que foram similares (P<0,05). Conclui-se que o pessário OB impregnado com MAP é higiênico, de baixo custo, prático e efetivo como para a sincronização de cios e IA em ovelhas.